Nama Insights

Erasca (ERAS)

Healthcare · Biotechnology · NASDAQ

Erasca (ERAS) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $4.99B and a free-cash-flow yield of -2.6%. Nama's AI scorecard rates it Sell, 2.7 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Sell · 2.7/10
Clearly negative, short of the bottom band. As of Nov 20, 2026.
Momentum
Leading · +421.2% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-44.0%
How far the last close sits under the highest price of the past five years.
Market cap$4.99B
Trailing P/E—
Price / book12.3
Price / sales—
FCF yield-2.6%
Dividend yield—
Gross margin0.0%
Operating margin0.0%
Net margin0.0%
Revenue growth (YoY)—
Revenue growth (3-yr annual)—
EPS growth (YoY)—
FCF/share growth (YoY)—
Beta0.7
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology

ERAS earnings

Next report: Mar 11, 2027 (Q4 2026, EPS estimate -$0.15). Beat the EPS estimate in 1 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 12, 2026 -$0.15 -$0.13 -15.4% $0
Q2 2026 Aug 11, 2026 -$0.14 -$0.11 -27.3% $0
Q1 2026 May 11, 2026 -$0.60 -$0.23 -160.9% $0
Q4 2025 Mar 12, 2026 -$0.10 -$0.11 +9.1% $0

ERAS analyst price target

Median target $23.00 from 10 analysts, ranging $20.00 – $35.00.

Biotechnology peers

TickerCompanyMarket capP/E
VRTX Vertex Pharmaceuticals $132.01B 27.4
REGN Regeneron Pharmaceuticals $95.52B 16.7
MRNA Moderna $80.65B —
ARGX argenx $59.24B 32.9
ONC BeOne Medicines $45.66B 50.8
RPRX Royalty Pharma $38.94B 12.8
RVMD Revolution Medicines $34.48B —
INSM Insmed $31.69B —
Explore live ERAS data on Nama Insights →

ERAS FAQ

Is ERAS a buy?
Nama's AI scorecard currently rates Erasca Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ERAS report earnings?
Erasca's next scheduled report is on Mar 11, 2027. Analysts expect EPS of -$0.15.
What is the ERAS price target?
The median analyst price target from 10 analysts is $23.00, with a range of $20.00 – $35.00.
Is ERAS Shariah compliant?
Nama's AAOIFI-style screen reads Erasca as Can't Tell. A figure the screen needs is missing, so it can't tell.